key: cord-0973811-xcw4yvsx
authors: Brandão, Antonio Adolfo Guerra Soares; de Oliveira, Cleyton Zanardo; Rojas, Salomon Ordinola; Ordinola, Amanda Ayako Minemura; Queiroz, Victoria Masi; de Farias, Danielle Leão Cordeiro; Scheinberg, Phillip; Veiga, Viviane Cordeiro
title: Thromboembolic and bleeding events in ICU patients with COVID-19: results from a Brazilian tertiary hospital
date: 2021-10-17
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.10.020
sha: 760328df61d6856f7bb95871f498fa909047958e
doc_id: 973811
cord_uid: xcw4yvsx

Objectives: Describe the incidence of thromboembolic events in adult patients with severe COVID-19 and identify clinical and laboratory correlates factors associated with these events. Design: Observational retrospective cohort of 243 adult patients with severe COVID-19 who were admitted to an intensive care unit at a Brazilian tertiary hospital. Results: The incidence of all thromboembolic events was 14.8%, in which 3.8% developed deep vein thrombosis, 7.8% pulmonary embolism, 2.5% acute myocardial infarction, 1.2% stroke, and 1.2% peripheral artery occlusion. Risk factors identified were D-dimer at admission higher than 3,000 ng/mL (p=<0.0013) and major bleeding (p=0.001). The cumulative risk of developing thromboembolic events at day 28 after ICU admission was 16.0%. The rate of major bleeding was 4.1%. After ROC curve analysis, the D-dimer cut-off at admission that correlated with thromboembolic events was 1,140.5 ng/mL. Conclusions: The rate of thromboembolic events in our study was lower than previously described. High D-dimer levels at admission was the leading risk factor and the optimal cut-off was 1,140.5 ng/mL. The occurrence of thromboembolic events did not have an impact on the median overall survival. The optimal anticoagulant strategy in this context still needs to be established.

In December 2019, in Wuhan, China, several pneumonia cases that progressed to severe acute respiratory syndrome (SARS) were reported. The coronavirus SARS-CoV-2 was identified as the etiological agent of this disease in the following month, later denominated COVID-19 Guan et al., 2020) . The association between other coronavirus and thromboembolic events was already recognized in both the 2003 SARS and 2012 Middle East Respiratory Syndrome (MERS) outbreaks (Giannis et al., 2020) . Similar thromboembolic events were noted in patients with SARS-CoV-2 after developing a significant inflammatory response, leading to a hypercoagulable state (Connors et al., 2020; McGonagle et al., 2020) .

In COVID-19 patients, abnormalities in coagulation tests, especially a higher D-dimer level, are associated with worse outcomes . Moreover, some studies showed that patients with COVID-19 admitted to intensive care units (ICU) have a high incidence of venous thromboembolism (VTE). Some authors report these complications in almost half of the patients (Middeldorp et al., 2020) . These events are more frequent in COVID-19 patients than in patients with acute respiratory distress syndrome (ARDS) of other etiologies (Helms et al., 2020) . Of note, a series of autopsies performed in deceased COVID-19 patients showed findings consistent with VTE in 58% of cases, even without prior clinical suspicion (Wichmann et al., 2020) .

Most of the published cohorts describing COVID-19 related VTE are from European or US groups (Middeldorp et al., 2020; Helms et al., 2020; Al-Samkari et al., 2020; Llitjos et al., 2020; Bilaloglu et al., 2020; Trigonis et al., 2020; Hippensteel et al., 2020) . Our study aimed to describe the incidence of thromboembolic events in a retrospective cohort of patients diagnosed with COVID-19 admitted to an ICU of a Brazilian tertiary hospital.

All consecutive patients admitted to the ICU of a Brazilian tertiary hospital between March 17 and June 18, 2020, with a confirmed diagnosis of COVID-19 were included in this retrospective study. SARS-CoV-2 detection in all cases was by PCR. Patients were followedup until the date of hospital discharge or death.

The primary endpoint was the occurrence of thromboembolic events, which were further divided into deep venous thrombosis (DVT), pulmonary embolism (PE), stroke, myocardial infarction, and acute peripheral artery occlusion.

The secondary endpoints were clinical or laboratory risk factors associated with thromboembolic events, overall mortality at day 28 after ICU admission, major bleeding according to the International Society of Thrombosis and Hemostasis, and the correlation between D-dimer levels and thromboembolic events by receiver operating characteristic (ROC) curve (Schulman et al., 2005) .

Patients with clinical suspicion of DVT had an ultrasound of extremities performed.

Pulmonary embolism was diagnosed by CT pulmonary angiography or, in unstable patients, a high pulmonary artery systolic pressure observed in an echocardiogram in the absence of other causes. Stroke was defined as central nervous system (CNS) infarction or ischemic stroke diagnosed by CNS imaging. The definition of prophylactic anticoagulant dose in this study was enoxaparin 40 mg QD or unfractionated heparin 5,000 IU BID or TID according to patients' body weight.

Data were summarized in terms of mean, standard deviation, median, minimum, and maximum when the variables were quantitative, frequency, and percentage for qualitative variables. Simple logistic regression was used to verify the difference between thromboembolic events (Yes / No) and the calculated Odds Ratio. Multiple model logistic regression was used to determine the effect of combinations of variables. A cut-off value for D-dimer was determined using ROC analysis. The value maximized the sensitivity and specificity of the discrimination between non-thromboembolic events patients and patients who experienced thromboembolic events during hospitalization. Previously, a cut-off value of 3,000 ng/mL was described as a factor associated with worse outcomes in patients with COVID-19 (Tang et al., 2020) . The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy and the respective 95% confidence intervals were estimated. A linear mixed-effect model was used to compare evolution for D-dimer in thromboembolic events. Overall survival (death from any cause) and thromboembolic events-free survival rates were estimated using a nonparametric KaplanMeier-estimator. The log-rank test was used to test the difference between survival (D-dimer and status), and the hazard ratio was calculated by Cox's regression. Data were analyzed with SPSS software (for Windows, v25.0). P < 0.05 was considered statistically significant.

Two hundred and forty-three consecutive patients admitted to the ICU with a confirmed diagnosis of COVID-19 were included in this study. The clinical and laboratory characteristics of the patients are summarized in Table 1 . The median follow-up duration was 10 days (mean, 16.4±18.7 days). Ninety-seven patients (39.9%) were female, and the median age was 63 years (range, 20-102). The median simplified acute physiology score (SAPS) III was 49 points (range 24-100). Thirty-three patients had a body mass index (BMI) higher than 35 kg/m² (13.6%), and 32 (13.2%) had a cancer diagnosis before admission. Median D-dimer at admission was 916 ng/mL (range 215-128,000). Forty-nine patients (20.2%) developed platelet counts lower than 100,000/mm³ during hospitalization. Anticoagulant therapy was employed in 222 patients (91.4%), with 175 (78.8%) receiving prophylactic dosing.

Mechanical ventilation was employed in 112 patients (46.1%).

Seventy-seven patients (33.5%) died between ICU admission and day 28, and 60.7% of patients who underwent mechanical ventilation had died The median overall survival (OS) after ICU admission was not reached at day 28. Patients with age ≥ 80 years had a median OS of 11 days after ICU admission and the median OS was not reached for patients with ages < 60 years and 60-79 years (p<0.001). Patients who underwent mechanical ventilation had a median OS of 15 days compared to a median OS not reached in those who were not ventilated (p<0.001). The median OS was not reached for both patients who received prophylactic anticoagulant dosing and for patients who received therapeutic dosing (p=0.079). Patients who developed thrombocytopenia during hospitalization had a median OS of 17 days versus not reached for those who did not (p<0.001). Patients with a prior history of cancer had a median OS of 27 days versus not reached for those who had not (p=0.025). The median OS for both patients who developed thromboembolic events and for those who did not was not reached (p=0.995).

During the study period, 51 patients (21%) had an ultrasound (US) of the extremities performed, 30 (12.3%) underwent CT pulmonary angiography, and 135 (55.5%) had an echocardiogram done. Thromboembolic events occurred in 36 patients (14.8%) ( Table 2) .

Venous thromboembolic events were DVT in 9 patients (3.7%) and PE in 19 (7.8%).

Cerebral venous thrombosis episodes were not observed. The rate of DVT was 17.6% in patients who had an US performed. Arterial thromboembolic events were stroke in 3 (1.2%), myocardial infarction in 6 (2.5%), and peripheral arterial occlusion in 3 patients (1.2%). The cumulative risk of thromboembolic events at day 28 after ICU admission was 16.0% ( Figure   1 ). In patients who developed thromboembolic events, the median time to these events occur was 2 days (range 0-76 days). Major bleeding was observed in 10 patients (4.1%) ( Table 2) .

Risk factors for thromboembolic events on univariate analysis (Table 3) were D-dimer at admission higher than 3,000 ng/mL (p=<0.0013) and major bleeding (p=0.001). These risk factors were also identified by logistic regression (Table 3) . For venous thromboembolic events (DVT and PE), D-dimer at admission higher than 3,000 ng/mL (p=<0.001) was the only risk factor identified.

The D-dimer cut-off at admission that correlated with thromboembolic events was 1,140.5 ng/mL by ROC curve analysis with an area under curve of 0.697 (95% CI 0.599-0.795) ( Figure 2) , a sensitivity of 62.5% (95% CI 43.7-78.9%), and a specificity of 63.3% (95% CI 56.1-70.0%). The positive predictive value (PPV) was 21.7% (95% CI 16.7-27.8%), the negative predictive value (NPV) of 91.2% (95% CI 86.7-94.2%) and an accuracy of 63.2% (95% CI 56.5-69.4%). When analysing the correlation between D-dimer levels > 3,000 ng/mL with thromboembolic events, the sensitivity was 40.6% (95% CI 23.7-59.4%), the specificity was 85.7% (95% CI 80.0-90.3%), a PPV of 31.7% (95% CI 21.3-44.4%), a NPV of 89.8% (95% CI 86.8-92.2%) and an accuracy of 79.4% (95% CI 73.6-84.4%). Figure 3 summarizes the evolution of D-dimer measurements during follow-up. D-dimer median levels at each time point were higher in patients who developed thromboembolic events (p=0.001) and in those who died (p=0.043).

In patients with baseline D-dimer higher than 1,140.5 ng/mL the median OS was 20 days and it was not reached for patients with D-dimer lower than 1,140.5 ng/mL (p<0.001) with a Hazard Ratio (HR) of 4.091 (CI 95% 2.467-6.785) (figure 4). The median OS was not reached for both patients with baseline D-dimer higher than 3,000 ng/mL and for those with lower than 3,000 ng/mL, with an OS of 53.7% at day 28 after admission versus 71.4%, respectively (p=0.028) and the HR was 1.782 (CI 95% 1.052-3.019).

Our report is the largest cohort regarding thromboembolic and bleeding events from Latin-American COVID-19 patients to date. We found a mortality rate of 33.5% and the median OS was not reached at day 28 after ICU admission. Of note, 62.3% of deaths (48/77) occurred during the first ten days. We found a incidence of 14.8% of thromboembolic events, further divided into 11.1% of venous thromboembolism and 4.9% of arterial events, and the cumulative risk to develop those events at day 28 after ICU admission was 16.0%. These results show a lower incidence of thromboembolic events than previously reported in other ICU cohorts (Table 4) (Middeldorp et al., 2020; Helms et al., 2020; Al-Samkari et al., 2020; Llitjos et al., 2020; Bilaloglu et al., 2020; Trigonis et al., 2020; Hippensteel et al., 2020) . The main risk factor identified for thromboembolic events was higher D-dimer levels, both higher than 3,000 ng/mL, a parameter already associated with poor prognosis in this group of patients and higher than 1,140.5 ng/mL, a cut-off identified after ROC curve analysis in our study. This cut-off was also a predictor of shorter overall survival, and patients who had a D-dimer level above 1,140.5 ng/mL had a 4.09 higher risk of death.

However, the cut-off of 3,000 ng/mL described previously had better accuracy in predicting patients who developed thromboembolic events. Other studies reported a higher sensitivity when using this cut-off, although with lower accuracy (Artifoni et al., 2020; Gibson et al., 2020 ). The D-dimer level was consistently higher during follow-up among patients who died and in patients who developed thromboembolic events. It is noteworthy that D-dimer levels seem higher in COVID-19 patients than in patients with bacterial pneumonia or other inflammatory condition in ICU patients .

Interestingly, mechanical ventilation did not have a significant impact on thromboembolic events, which was unexpected considering the correlation between higher d-dimers and both severity and thromboembolic events. This observation may suggest that d-dimer could be an independent variable of severity in this group of patients and that the optimal d-dimer cut-off with clinical significance still needs further studies. Our results did not show impact in overall survival for patients who received therapeutic anticoagulation compared with those who received anticoagulants at prophylactic dosing. Of note, the decision to whether use therapeutic or prophylactic anticoagulant dosing was at physician's discretion. We did not find a correlation between age, gender, and obesity with thromboembolic events, and this lack of correlation has been previously reported .

Major bleeding was also identified as a risk factor for thromboembolic events. A possible reason to this correlation is the inability to administer anticoagulants to these patients due to bleeding events, hence the pharmacological prophylaxis to thromboembolic events could not be used. Major bleeding rate was 4.1%, similar to other cohorts (Wichamann et al., 2020), and relatively low, considering that 91.4% of our patients received anticoagulants. Overall survival was not influenced by the occurrence of thromboembolic events, although this must be addressed cautiously due to the low rate of events.

Our study has limitations since we analysed retrospective data collected from patients from a single centre during what is called "the first wave" in 2020. Data in the thrombosis risk in the so-called "variants" could differ. We were not able to collect detailed data regarding prior patients' comorbidities. The incidence of thromboembolic events may have been underestimated due to underdiagnosis as a VTE screening strategy was not employed, such as routine US; thereby, only patients with symptomatic thromboembolic events were diagnosed.

The rate of DVT in patients who underwent US was low (17.6%); hence a systematic US policy may not be warranted due to the risk of contamination in health care personnel. On the other hand, the high adhesion to pharmacological prophylaxis of VTE, based on our institutional protocols, may have favorably contributed to our results. We did not perform a routine anti-Xa assay to evaluate the prophylactic anticoagulation's efficacy, which may identify patients eligible for a more intensive anticoagulation strategy (Dutt et al., 2020) . We also did not have access to data regarding thromboembolic events post-discharge, and we did observe patients who developed thromboembolic events after 76 days of admission, suggesting that the thromboembolic risk may persist after ICU and hospital discharge.

However, most of the thromboembolic events occurred in the first 2 days after ICU admission.

In conclusion, the correlation of thromboembolic events and severe COVID-19 is striking.

The optimal anticoagulant strategy in this context is a matter of debate (Thachil et al., 2020; Moores et al., 2020; Orsi et al., 2020) . Two clinical trials (INSPIRATION Investigators et Author Contributions: AAGSB designed the study, collected and analysed the data, drafted and revised the paper. CZO wrote the statistical analysis plan, cleaned and analysed the data, and revised the paper. SOR, AAMO and VMQ collected the data and revised the paper.

DLCF and PS designed the study and revised the paper. VCV designed the study, collected and analysed the data, and revised the paper.

Approval was not required. 

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

COVID-19 and its implications for thrombosis and anticoagulation

Thromboprophylaxis in COVID-19: Anti-FXa-the Missing Factor?

Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

Probative Value of the D-Dimer Assay for Diagnosis of Deep Venous Thrombosis in the Coronavirus Disease 2019 Syndrome

Clinical Characteristics of Coronavirus Disease 2019 in China

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Prevalence of venous thromboembolism in critically ill patients with COVID-19

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease

Guidance on diagnosis, prevention and treatment of thromboembolic complications in COVID-19: a position paper of the Brazilian Society of Thrombosis and Hemostasis and the Thrombosis and Hemostasis Committee of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Patients Receiving Prophylactic Anticoagulation

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis

Incidence and Risk Factors of Deep Vein Thrombosis in Hospitalized COVID-19 Patients

Baseline Simplified Acute Physiology Score (SAPS) III -median

Acknowledgments: We thank all the staff involved in the critical care of the patients.Competing interests: nothing to disclose.Funding source: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Thromboembolic events Bleeding events Middeldorp, et